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Abstract
Background: Adeno-associated virus type 2 (AAV2) preferentially integrates its DNA at a ~2 kb region of human
chromosome 19, designated AAVS1 (also known as MBS85). Integration at AAVS1 requires the AAV2 replication (Rep)
proteins and a DNA sequence within AAVS1 containing a 16 bp Rep recognition sequence (RRS) and closely
spaced Rep nicking site (also referred to as a terminal resolution site, or trs). The AAV2 genome is flanked by
inverted terminal repeats (ITRs). Each ITR contains an RRS and closely spaced trs, but the sequences differ from
those in AAVS1. These ITR sequences are required for replication and packaging.
Results: In this study we demonstrate that the AAVS1 RRS and trs can function in AAV2 replication, packaging and
integration by replacing a 61 bp region of the AAV2 ITR with a 49 bp segment of AAVS1 DNA. Modifying one or
both ITRs did not have a large effect on the overall virus titers. These modifications did not detectably affect
integration at AAVS1, as measured by semi-quantitative nested PCR assays. Sequencing of integration junctions
shows the joining of the modified ITRs to AAVS1 sequences.
Conclusions: The ability of these AAVS1 sequences to substitute for the AAV2 RRS and trs provides indirect
evidence that the stable secondary structure encompassing the trs is part of the AAV2 packaging signal.
Background
Adeno-associated viruses (AAVs) are mammalian parvo-
viruses that typically require a helper virus, such as an
adenovirus or herpesvirus for productive replication [1].
Multiple AAV serotypes have been described. The most
detailed information is available for AAV serotype 2
(AAV2), the first human isolate. In the absence of
helper virus, AAV2 preferentially integrates into a
region of human chromosome 19 (19q13.4ter) referred
to as Adeno-Associated Virus Site 1, or AAVS1 [2-5]. In
cultured cells infected with a high multiplicity of virus,
approximately 70% of integration events have been
reported to occur at AAVS1 [6-9]. Site-specific integra-
tion would be useful for many gene therapy applications,
but most recombinant AAV vectors do not utilize the
ability of AAV2 to integrate site-specifically [10].
AAV2 has a 4.7 kb single-stranded DNA genome
flanked at each end by 145 base inverted terminal
repeats (ITRs) [11]. The ITRs are required for viral
replication and packaging and occur in two forms,
referred to as “flip” and “flop” (Fig. 1) [12-14]. The flip
and flop conformations are a consequence of the rolling
hairpin mechanism of AAV2 replication [15]. AAV2
contains two open reading frames that occupy most of
the remainder of the genome. The right open reading
frame encodes three capsid proteins, VP1, 2 and 3
[16,17]. The left open reading frame encodes the four
nonstructural replication proteins [18,19]. The large
replication proteins, Rep78 and 68, possess sequence-
specific DNA binding, ATPase, helicase and sequence-
specific, strand-specific endonuclease activities [20-23].
Rep 68 or 78 are required for AAV2 replication [24,25].
Each ITR forms a double hairpin, or “T” shaped struc-
ture (Fig. 1). The ITRs contain a 16 bp, double-stranded,
Rep recognition sequence (RRS), consisting of four
imperfect GCTC repeats [22,26], and a Rep68/78 nicking
site, or terminal resolution site (trs) [20]. Rep68/78 binds
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[29], allowing the formation of a specific secondary struc-
ture at the trs [30,31]. Rep78/68 nicks one strand of the
DNA between the two adjacent thymine residues in the
trs [20,32], creating a free 3’-end which is required for
replication of the end of the AAV2 genome. Several lines
of evidence indicate that replication and packaging are
coupled [33]. Capsid interactions have been observed
with all four Rep proteins [34] and single-stranded AAV2
DNA also does not accumulate in the absence of capsids
[35] or Rep 52/40 [25]. The helicase function of Rep52/
40 is believed to be required to insert the replicated DNA
into the pre-formed capsids and the DNA is inserted
from the 3’-end [36].
AAVS1 contains a RRS [26] and a closely spaced trs
[37], an arrangement that is thought to be unique in the
human genome [5,38]. A 33 bp region of AAVS1
encompassing the RRS and trs is sufficient to target
integration of wild-type AAV2 into an episome [39-41].
Rep68/78 is also required for AAV2 integration at
AAVS1 on chromosome 19 [8,42,43]. Sequence data are
available for a number of AAV2-AAVS1 junctions
[2,40,44]. AAV2 junctions within AAVS1 have been
shown to occur only on one side of the AAVS1 trs.
AAVS1 DNA also serves as a Rep68/78-dependent,
unidirectional origin of replication in vitro [37]. These
observations are consistent with DNA synthesis from
the nicking site being part of the integration mechanism.
More recent reports have shown the encapsidation of
AAVS1 sequences as a byproduct of AAV2 production
[45]. Encapsidation of sequences containing a cryptic
RRS/trs combination found at the p5 promoter of AAV2
[46-48], as well as encapsidation of prokaryotic sequences
linked to AAV2 ITRs have also been reported when a
plasmid-based packaging system was used [49]. These
observations suggest degeneracy in the sequences that
can be used as AAV2 replication and packaging signals.
In this report we have extended the existing homology
between the ITR and AAVS1 by replacing 61 bp of
sequence containing the RRS and trs with 49 bp of
AAVS1 sequence containing the AAVS1 RRS and trs.
We find that AAV2 modified in this way can replicate,
package and integrate similar to the wild-type virus.
Results
Replacement of the AAV2 ITR RRS and trs with
chromosome 19 DNA
The AAV2 ITR forms an extensive secondary structure
and is composed of seven regions, a, a’,b ,b ’,c ,c ’ and d
(Fig. 1A). The ITRs in the AAV2 infectious clone
Figure 1 Structure of the wild-type AAV2 and modified ITR. (A) The AAV2 ITR is composed of seven regions, a, a’,b ,b ’,c ,c ’ and d, and forms an
extensive secondary structure. The b, b’,ca n dc ’ regions exist in two configurations, “flip” and “flop.” The wild type ITR is shown in the flip
configuration. (B) A modified version of the ITR, in which the a, a’ and d regions are replaced with AAVS1 DNA, was designed in the flop configuration.
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sites were used to replace the ITRs with a synthetic ITR
obtained from a commercial supplier. The a, a’ and d
regions are replaced with AAVS1 DNA in the modified
ITR (Fig. 1B).
Packaging and replication
A two plasmid system was used to package AAV2. One
plasmid contained the AAV2 genome with wild-type
and/or modified ITRs. The second plasmid expressed
adenovirus genes that promote AAV replication. The
two plasmids were used to co-transfect a human
embryonic kidney cell line expressing the adenovirus E1
gene (Stratagene HEK293 cells). The cells were later
lysed to collect the packaged virus. During this proce-
dure DNA that was not packaged as virus was removed
by nuclease treatment. Hybridization analysis was used
to measure the amount of virus DNA that was resistant
to nuclease treatment. Virus proteins were removed by
protease treatment prior to applying the virus DNA to
the membrane. To calibrate the number of genomes
that were packaged, various dilutions of a linearized
AAV2 plasmid were denatured and applied to the mem-
brane. For the virus titer determination, the membrane
was hybridized to random primer radiolabeled AAV2
DNA from the wild-type AAV2 plasmid. The results are
shown in Fig. 2. Three-fold dilutions of nuclease-
resistant DNA were applied to the membrane in part A
of the figure. The row labeled wt is nuclease-resistant
AAV2 DNA derived from cells co-transfected with the
adenovirus helper plasmid and pSub201(-). The virus
DNA in the row labeled 108 was made using pVM108.
pVM108 is a pSub201(-) derivative in which both ITRs
are replaced with the modified sequence. The virus
DNA in rows labeled 112 and 141 was made from
pVM112 and pVM141, respectively. pVM112 and
pVM141 are pSub201(-) derivatives in which only one
ITR is replaced with the modified sequence. pVM112
and pVM141 have an additional 49 bp of AAVS1
sequence (beginning 1509 bp from the AAVS1 trs)
between the right ITR and the cap gene. Approximately
the same amount of AAV2 was packaged with genomes
containing wild-type, or one or two modified ITRs. The
titers are in the range of 10
12 packaged virus genomes
per 75 cm
2 flask of cells.
Virus DNA replication in plasmid-transfected cells
was analyzed by using the Southern blotting procedure.
A map of the pSub201(-) vector used to make AAV2
containing two wild type ITRs is shown in Figure 3A.
As shown in Figure 3B, the AAV2 genome is located
within a PvuII fragment of the vector. The vector maps
for pVM108 (both ITRs modified) and pVM113 (left
ITR modified) are similar to pSub201(-). In all three
vectors the ITRs are located between the PvuII and
XbaI sites. Figure 3C is a Southern analysis of AAV2
replication in cells transfected with pSub201(-), pVM108
or pVM113. The cells were cotransfected with an ade-
novirus helper plasmid. Equal amounts of genomic
DNA were loaded in each of the sample lanes. The
membrane was probed with randomly labeled pSub201
(-) DNA. Replicated and input plasmid DNA were dif-
ferentiated by DpnI treatment, which only digests bacte-
rially methylated DNA. The major band of replicated
DNA in each of the sample lanes is approximately 5 Kb,
which corresponds to size of the AAV2 genome. A sec-
ond replication product migrates at approximately
9.5 Kb. These bands correspond to the two major
AAV2 replication intermediates, referred to as replica-
tion form monomer (RFM) and dimer (RFD). The ratio
of these intermediates appears to be the same for each
of the constructs tested. Less DNA replication was
detected in the pVM108 and pVM113 samples lanes
than with pSub201(-). The replication defect is more
pronounced with pVM108 and somewhat intermediate
with pVM113. For each vector, similar amounts of DNA
replication are detected at 24 hours and 48 hours.
An approximately 4 Kb band of replicated DNA is
detected in the pVM108 sample lanes in Figure 3C that
is not detected in the other lanes. The identity of this
band is confirmed by the Southern analysis in Figure
3D. Digestion of the genomic DNA with ClaI indicates
Figure 2 Packaging comparisons between the wild-type and
modified viruses. (A) Dot blot analysis of 3-fold serial dilutions of
nuclease-resistant AAV2 DNA made using pSub201(-) (wt), pVM108
(108) pVM112 (112) or pVM141 (141). The first dot in each row has
the nuclease-resistant DNA obtained from 5 μl of virus supernatant.
(B) Standards. The indicated amount of linearized and denatured
pSub201(-) was applied to the same membrane. All samples were
probed with random primer radiolabeled AAV2 DNA.
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Figure 3 Viral DNA replication. (A) Restriction map of pSub201(-). (B) Location and orientation of the AAV2 genome in pSub201(-).
(C) Southern blot of genomic DNA from cells cotransfected with an adenovirus helper plasmid and the indicated AAV2 plasmids. The
membrane was probed with random primer
32P-labeled, linearized pSub201(-). The molecular weight marker is homologous to the backbone
portion of pSub201. (D) Southern blot of genomic DNA from cells cotransfected with an adenovirus helper plasmid and pVM108. The membrane
was probed with random primer labeled pSub201. The pSub201(-) marker was made by running XbaI and PvuII digests in the same lane.
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bone portion of pSub201(-). The marker lane in Figure
3D was made by combining separate PvuII and XbaI
digestions of. pSub201(-). The migration of these bands
can be used to determine that the ~4 Kb pVM108 repli-
cation product contains AAVS1 ITRs located between
the PvuII and XbaI sites. The bands do not align exactly
because the AAVS1 modified ITRs are slightly smaller
than the wild type ITRs in pSub201(-).
Site-specific integration
A nested PCR assay was used to detect integration at
AAVS1. With this assay one primer set is designed to
anneal to AAV2 and the second primer set is designed
to anneal to AAVS1. The locations of the primer pairs
that were used are diagramed on maps of AAV2 and
AAVS1 in Figure 4A. Because the Rep primers and ITR
primers are close to the ends of AAV2, the locations of
the junctions within AAVS1can be estimated from the
s i z e so ft h eP C Rp r o d u c t s( F i g .4 Ba n d4 C ) .T h em a j o r
~1 Kb bands in Figures 4B and 4C indicate a cluster of
junctions in the area of the AAVS1 trs and RRS. This
area of AAVS1 has been previously noted as a junction
hotspot [40,44].
Bohenzky et al. reported the conversion of a mutated
ITR to the wild-type sequence, when only one ITR was
modified [50,51]. Since the mechanism of this reversion
is not entirely clear, we needed to eliminate this as a
possibility for our vector in which both ITRs are
mutated. Using a primer set specific for the wild-type
ITR does not produce an amplification product for virus
produced from pVM108 (Fig. 4C), demonstrating that
the ITRs in pVM108 have not been converted to wild-
type during virus production. Several integration junc-
tions were cloned and sequenced. Figure 5A, B and 5C
show the sequences that were recovered. The sequence
in Figure 5A is the sequence of the integration junctions
amplified from cells infected with virus produced from
pVM108 and pVM113 using the AAV2 rep primers
(Fig. 4A). All of the junctions amplified from cells
infected by virus made from these constructs using the
rep primers contain this sequence, which appears to be
the modified ITR sequence joined to AAVS1 at the
RRS/trs region. The sequences in Figure 5B were ampli-
fied from cells infected with wild-type virus using the
ITR-specific primers. The sequences in Figure 5C were
amplified from cells infected with virus produced from
pVM113 using the ITR-specific primers. These results
confirm that the PCR products shown in Figure 4 are
AAV2-AAVS1 junctions.
Discussion
AAV2 has a relatively low frequency of integration
[9,52,53]. This is probably due to the fact that, unlike
retroviruses, integration is not an obligatory part of the
AAV2 life cycle. We and others have noted that the
majority of AAV2/AAVS1 junctions occur at short
regions of homology between AAV2 and AAVS1 [7,44].
We therefore hypothesized that increasing sequence
homology between AAV2 and AAVS1 might increase
either the frequency or site-specificity of AAV2 integra-
tion. One approach was to insert DNA sequences from
AAVS1 into the AAV2 genome. The amount of
sequence that can be added is limited by the packaging
capacity of AAV2 [54]. Westarted with a modest insert
of 49 bases in an area of AAV2 that would not interfere
with replication or packaging. Our second approach was
to expand an existing region of homology by replacing
the RRS/trs region of the AAV2 ITRs with the corre-
sponding region from AAVS1. This second strategy does
not increase the size of the AAV2 genome, but there
was concern that the AAVS1 sequence might not con-
tain all of the sequence elements required for AAV2
replication and packaging.
We did not detect a marked increase in integration
efficiency as indicated by the intensity of bands on our
gels of PCR products (Fig. 4 and data not shown) with
our modified viruses. We also failed to see a reproduci-
ble increase in integration site specificity, which would
have been indicated by a reduced size range for the PCR
products (Fig. 4 and data not shown). We interpret
these results as indicating that the integration process is
more similar to non-homologous end-joining than
homologous recombination, even with the increased
homology. This interpretation is consistent with the
observations of Daya et al. who showed that DNA ligase
IV and DNA PKcs can affect the ratio of AAVS1 to
non-AAVS1 integration events by AAV2 [55]. It should
be noted however that a small increase in the number
of specific junctions mediated by the increased homol-
ogy might have been masked by the natural clustering
of junctions occurring in these areas.
Our results do indicate that the RRS and trs elements
from AAVS1 and AAV2 are functionally interchangeable.
A strand packaging bias was observed by Zhou et al [56]
when they deleted 18 bases of one d-sequence in the con-
text of a recombinant AAV2 vector plasmid containing a
single modified ITR with two d sequences. Their inter-
pretation of their data was that the deleted 18 bases con-
tained a packaging signal. In our AAVS1-substituted ITR,
these 18 bases are almost completely changed and/or
deleted. We have previously demonstrated the existence
of stable secondary structures in single-stranded versions
of the sequences roughly centered on the AAV2 and
AAVS1 trs [31]. We believe that these secondary struc-
tures, thought to be stem-loops, based on sequence ana-
lysis of multiple AAV serotypes [30], function as a
critical packaging signal. An 18 base pair deletion of the
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Page 5 of 11Figure 4 Site-specific integration at AAVS1. (A) Diagrams (not to scale) of the AAV2 and AAVS1 primer pairs used in nested PCR assays. Each
arrow represents a set of two nested primers used in a PCR assay. The number below the AAV2 rep primer set indicates the number of bases
from the 5’ end of the second primer to the end of the AAV2 genome. The number below the AAVS1 primer set indicates the number of bases
from the trs to the 5’ end of the second primer in the AAVS1 primer set. (B) Nested PCR assays using the AAVS1 primer set with the AAV2 rep
gene primer set. The templates were genomic DNA isolated from HeLa cells infected with the indicated volumes of AAV2-containing
supernatants produced using pSub201(-) (wt), pVM108 (108) or pVM113 (113). PCR products were resolved on a 1% agarose gel and stained with
ethidium bromide. Single primer controls were done by using only the AAVS1 primer or the AAV2 primer in the second PCR. The template for
the single primer controls was DNA from cells infected with 100 μl AAV2. (C) Nested PCR assays using the AAVS1 primer set with the AAV2 ITR
primer set. The single primer control used only the AAV2 primer in the second PCR.
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stem-loop structure [30,31]. The 11 base sequence from
AAVS1 which essentially replaces the 18 bases deleted by
Zhou et al. [56] in our mutated ITR has only has 2, non-
adjacent, bases of sequence identity with the wild-type
AAV2 sequence (Fig. 1). It is therefore a reasonable infer-
ence that the stable secondary structure, the only other
known commonality between the two sequences, is part
of the packaging signal.
Having an intact trs as part of the packaging signal
would have a selective advantage because it would pre-
vent packaging of virus genomes in which the trs had
been prematurely cleaved by Rep68/78 or cellular endo-
nucleases. An intact trs is required for productive
infection [14]. In the packaged, single-stranded form of
the AAV2 genome, only the 3’ end of the genome
would have an intact trs stem-loop (Fig. 1). This trs
stem-loop/packaging signal hypothesis is also consistent
with the observations that the 3’ end of the AAV2 gen-
ome enters the pre-formed capsid before the 5’ end and
that packaging appears to be driven by the 3’ to 5’ heli-
case activity of the Rep proteins [29,33,36,57,58].
A fundamental question in virology is centered on the
origins of virus DNA sequences. The RRS/trs combina-
tion at the MBS85 gene (the AAVS1 locus in humans)
has also been detected in mice and African green mon-
keys [59-62]. Although it cannot be formally ruled out
that this sequence is the remnant of an AAV2
Figure 5 DNA sequence analysis of the integration junctions. Bases that are shared by AAVS1 and the packaged virus are underlined.
(A) The sequence of the integration junctions detected in cells infected with virus made using the pVM108 or pVM113 constructs using a
combination of the AAV2 rep primers and the AAVS1 primers in the integration assay. The XbaI site is indicated by italics. (B) The sequences of
the integration junctions detected for the wild-type virus using a combination of the AAV2 ITR primers and the AAVS1 primers in the integration
assay. (C) The sequences of the integration junctions detected for virus made using the pVM113 construct using a combination of the AAV2 ITR
primers and the AAVS1 primers in the integration assay. Bases at the junctions that do not appear to belong to either sequence are indicated
lower case. The last junction contains additional AAV2 homology that is not indicated in the figure.
McAlister and Owens Virology Journal 2010, 7:218
http://www.virologyj.com/content/7/1/218
Page 7 of 11integration event that occurred prior to the rodent-pri-
mate evolutionary divergence, a more intriguing possibi-
lity is that the AAV2 origin of replication is derived
from this genomic sequence.
One final concern is that the packaged virus that was
believed to be modified may have been wild-type rever-
tants. The integration assays shown in Fig. 4 make this
possibility highly unlikely. Using AAV2 ITR primers
designed specifically to detect the wild-type ITRs, we
were not able to detect junctions when the virus with
two modified ITRs was used to infect cells. In addition,
we were able to clone and sequence junctions with
AAVS1 that appear to have the modified ITR joined to
AAVS1 (Fig. 5).
Conclusions
The ability of these AAVS1 sequences to substitute for
the AAV2 RRS and trs provides indirect evidence that
the stable secondary structure encompassing the trs is
part of the AAV2 packaging signal. These results also
suggest a level of sequence flexibility that could promote
rapid evolutionary divergence of AAVs.
Methods
Plasmids and modification of the AAV2 ITR
A synthetic ITR of the following sequence was supplied
to us in a cloning vector by Blue Heron Biotechnology
(Bothell, WA). 5’-TCT AGA GTG GTG GCG GCG GTT
GGG GCT CGG CGC TCG CTC GCT CGC TGG GCG
GGC GCG GGC GAC CAA AGG TCG CCC GAC GCC
CGG GCT TTG CCC GGG CGC GCC CGC CCA GCG
AGC GAG CGA GCG CCG AGC CCC AAC AGC TG-
3’. This sequence and the ITRs in the AAV2 infectious
clone pSub201(-) (a kind gift from Dr. R. Jude Samulski)
are flanked by Xba I and Pvu II sites [63]. A subcloning
strategy using these restriction sites was employed to
replace either the left, right or both ITRs in pSub201(-)
with the ITR synthesized by Blue Heron Biotechnology.
As indicated in Table 1, pVM108 is a pSub201(-) deriva-
tive in which both ITRs are replaced with the ITR modi-
fied to match AAVS1. pVM113 is a pSub201(-) derivative
in which the left ITR is replaced with the ITR modified
to match AAVS1. pVM112 is similar to pVM113.
pVM112 contains an additional 49 bp of AAVS1 DNA
that was made by annealing the following oligonucleo-
tides: 5’-CTA GAG CCT GGA CAC CCC GTT CTC
CTG TGG ATT CGG GTC ACC TCT CAC TCC TTT
ACT AGT-3’ and 5’-CTA GAC TAG TAA GGA GTG
AGA GGT GAC CCG AAT CCA CAG GAG AAC GGG
GTG TCC AGG CT-3’. When annealed, these oligonu-
cleotides produce 5’ overhangs that are compatible
with Xba I. The sequence was cloned into the Xba I site
adjacent to the right ITR in pVM112. pVM141 is a
pSub201(-) derivative in which the right ITR is replaced
with the ITR modified to match AAVS1. pVM141 also
contains the additional 49 bp of AAVS1 DNA present in
pVM112. In pVM141 the DNA was cloned into the XbaI
site adjacent to the left ITR. The sequence is in the same
orientation in both vectors.
Transfection of HEK293 cells and preparation of virus
supernatants
To produce virus, HEK293 cells (Stratagene) which con-
t a i nt h ea d e n o v i r u sE 1g e n ew e r ec o - t r a n s f e c t e dw i t h
the E1 deleted adenovirus helper plasmid pHelper (Stra-
tagene) and the ITR-containing AAV2 plasmids using
the calcium phosphate co-precipitation method. To per-
form this procedure, 250 μl of 2× HBS (280 mM NaCl,
1.5 mM Na2HPO4, 50 mM HEPES, pH 7.1) was added
to a 250 μlv o l u m eo f0 . 5MC a C l 2 containing 14 μg
pHelper and 14 μg of the AAV plasmid and immediately
added to a 75 cm
2 f l a s ko f~ 8 0 %c o n f l u e n tS t r a t a g e n e
HEK293 cells that had been split 1:5 the previous day
into DMEM media (Invitrogen) with 2 mM L-glutamine
and 10% fetal bovine serum. After 2 days the cells were
scraped from the plates, washed once with PBS and sus-
pended in 0.5 ml cell lysis buffer (0.15 M NaCl, 50 mM
Tris-HCl, pH 8.5). Cells were lysed by three cycles of
freezing at -80°C and thawing. Unpackaged DNA was
removed by adding 50 μl of Benzonase (Novagen) and
incubating at 37°C for 2 hours.
Determination of viral titers
For titration of packaged virus genomes, DNA was iso-
lated from 25 μl of the virus supernatant. The volume
was adjusted to 200 μl with a final concentration of
10 mM EDTA and 0.5% SDS. Next, 18.6 μgo fp r o t e i -
nase K (Invitrogen) was added and the solution was
incubated for 1 hr at 37°C. Proteins were removed by
phenol-chloroform extraction. The DNA was ethanol
precipitated with 10 μg of glycogen (Roche). The DNA
was resuspended in 0.5 M NaOH, 1.5 M NaCl and
hybridized to a positively charged nylon membrane
(Hybond nucleic acid transfer membrane, GE Health-
care, Buckinghamshire, UK) using a dot blot apparatus.
pSub201(-) contains an AAV2 genome flanked by Pvu II
Table 1 Plasmid constructs used to make the modified
viruses used in this study
aOther
Left ITR Right ITR AAVS1 Insert
pSub201(-) wt wt No
pVM108 AAVS1 AAVS1 No
pVM112 AAVS1 wt Yes
pVM113 AAVS1 wt No
pVM141 wt AAVS1 Yes
aAs described in the methods section, pVM112 and pVM141 contain an
additional 49 bp of AAVS1 DNA.
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dard. To probe the blot, pSub201(-) was digested with
XbaI and ClaI. The 4310 bp XbaI fragment of the
AAV2 genome from pSub201(-) was gel purified and
random primer labeled using [a-
32P]dCTP and oligola-
beling beads (Ready to go DNA labeling beads, GE
Healthcare, Buckinghamshire, UK). Hybrisol (Millipore,
Temecula, CA) was used for the hybridization.
Southern blotting analysis of virus replication
Total DNA from HEK293 cells transfected in parallel
with those used for the preparation of virus supernatants
w a si s o l a t e du s i n gaD N e a s yt i s s u ek i t( Q I A G E N ,V a l e n -
cia, CA) 24 and 48 hours post transfection. Some samples
were pre-treated with Dpn I to degrade input plasmid.
Two micrograms of DNA from each sample was resolved
on a 1% agarose gel and transferred to positively charged
nylon membrane (Hybond nucleic acid transfer mem-
brane, GE Healthcare, Buckinghamshire, UK) for South-
ern blotting analysis. Briefly, the DNA was first
fragmented by soaking the gel in several volumes of 0.25
M HCl for 10 minutes. The gel was washed for several
minutes with water and DNA was denatured by soaking
the gel in 1.5 M NaCl, 0.5 N NaOH for 30 minutes. The
gel was placed front down on a solid support covered by
a piece of Whatman 3 mm paper long enough to drape
into a reservoir of 10× SSC (KD Medical, Columbia,
Maryland). The positively charged nylon membrane was
placed on the back of the gel below a stack of paper
towels. After a 16 hour transfer the membrane was
washed several times with 5× SSC and dried in bright
light. The membrane was probed with random primer
labeled pSub201(-). The pSub201(-) probe was made
using [a-
32P]dCTP and oligolabeling beads (Ready to go
DNA labeling beads, GE Healthcare, Buckinghamshire,
UK). Hybrisol (Millipore, Temecula, CA) was used for
the hybridization. A 1 Kb DNA ladder (Fermentas, Glen
Burnie, MD) and pSub201(-) were used as DNA markers.
Several of the bands in the 1 Kb DNA ladder contain
DNA that is in pSub201(-) and hybridize to the probe.
The pSub201(-) marker was made by combining PvuII
and XbaI digests of pSub201(-). The digestions were
stopped with 5 mM EDTA before combining.
Integration assays
A2 5c m
2 flask of ~25% confluent HeLa cells was infected
for 2 hours in medium without fetal bovine serum (FBS).
After 2 hours the medium was replaced with medium
containing 10% FBS. Cells were harvested 48 h after
infection, and genomic DNA was isolated using a DNeasy
tissue kit (QIAGEN, Valencia, CA). Several combinations
of AAV2 and AAVS1 primer pairs were used to detect
integration by nested PCR. For the nested PCR assay 50
ng of genomic DNA and 100 ng of each primer in a 50-μl
reaction volume were used in the first round of PCR
amplification. After an initial incubation for 4 min at 94°
C, the reaction mixture was subjected to 28 cycles of
PCR amplification for 1 min at 94°C, 1 min of annealing
at 63°C, and 3 min at 72°C, using FastStart DNA poly-
merase (Roche). One percent of the amplification pro-
duct was diluted into a new reaction mixture containing
the second pair of primers. The PCR parameters were
the same as those for the first amplification. The follow-
ing primer sets were used. In each set the first primer
listed was used in the first amplification and the second
primer was used in the second amplification. AAV2 rep
5’-CAC CCA GTT CAC AAA GCT GTC AGA AAT G-
3’ and 5’-TCG CTG GGG ACC TTA ATC ACA ATC
TC-3’,A A V 2c a p5 ’-CAG GAC AGA GAT GTG TAC
CTT CAG GG-3’ and 5’-TGG ACA CTA ATG GCG
TGT ATT CAG AGC-3’,A A V 2I T R5 ’-GCC TCA GTG
AGC GAG CGA G-3’ and 5’-GCA GAG AGG GAG
TGG CCA-3’, AAVS1 5’-AGG CAG ATA GAC CAG
ACT GAG CTA TGG-3’ and 5’-CAG GGA AGG AGA
C A AA G TC C AG G A - 3 ’. PCR products were resolved
on a 1% agarose gel and stained with ethidium bromide.
Cloning and sequencing of PCR-amplified junctions were
performed as described previously [44].
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